UNDERSTANDING CANCER

DEFINITION, TREATMENT, EMERGING APPROACHES
IMMUNE ROLE, AND PREVENTION

Table of Contents

CHAPTER 1
What is Cancer 3

CHAPTER 2
Conventional Medical Treatments 4

CHAPTER 3
Alternative and Emerging Approaches 5

CHAPTER 4
Repurposing Antiparasitic Drugs: Ivermectin and Fenbendazole 7

CHAPTER 5
Cancer Prevention: Known Strategies & Emerging Research 8

CHAPTER 6
Conclusion: Clarity Through Science & Hope 12

CITATIONS 13



CHAPTER 01

What Is Cancer?

Cancer is a broad group of diseases characterized by the uncontrolled growth of abnormal cells that can invade nearby tissues and spread to other parts of the body (metastasize) [1]. It is both a genetic and metabolic disease, arising from DNA mutations that disrupt normal cell regulatory mechanisms as well as metabolic alterations that fuel cancer growth. Many emerging therapies target the metabolic dimension of cancer, such as by lowering insulin and insulin-like growth factor levels[2]. There are over 200 distinct types of cancer, since virtually any cell type in the body can undergo malignant transformation. Despite their diversity, all cancers share the hallmark feature of cells growing and dividing without the usual controls, often forming a mass called a tumor and, in malignant cases, gaining the ability to migrate through the bloodstream or lymphatic system to colonize distant organs[1]. This combination of unchecked growth and potential for spread makes cancer a particularly challenging set of diseases to treat.

ALL CANCERS SHARE THE HALLMARK FEATURE OF CELLS GROWING AND DIVIDING WITHOUT THE USUAL CONTROLS.

How Cancer Develops:

The development of cancer is usually a multi-step process. Cells accumulate genetic alterations (through heredity, environmental exposures, or random errors in DNA replication) that confer growth advantages [3]. Over time, these changes allow cells to ignore normal growth-inhibitory signals and evade programmed cell death. Cancer cells also stimulate the formation of new blood vessels to feed growing tumors (angiogenesis) and can disable immune system brakes that would normally eliminate abnormal cells. Eventually, malignant cells may invade surrounding tissue and metastasize to establish secondary tumors in other organs, which is often the life-threatening aspect of cancer.[3]

CHAPTER 02

Conventional Medical Treatments

For many decades, the backbone of cancer treatment has consisted of three primary conventional modalities: **surgery, radiation therapy,** and **chemotherapy** [4]. These standard treatments are often used in combination, depending on the cancer type and stage, to maximize effectiveness. Below is an overview of each:

Surgery [5]**:** Surgical removal of the tumor is one of the oldest and most effective cancer treatments. If a cancer is detected early and is confined (localized) to one area, surgery can often eliminate it by physically cutting out all visible cancerous tissue. Surgery is typically the first-line treatment for many solid tumors and can be curative for early-stage cancers before they have spread. It can also help debulk (shrink) tumors to alleviate symptoms or to enable other treatments to work better. However, surgery alone may not be sufficient if cancer cells have already spread microscopically, which is why additional therapies are frequently given after surgery (adjuvant therapy).

Radiation Therapy [6]**:** Radiation uses high-energy X-rays or other particles to destroy cancer cells or damage their DNA so they cannot continue to grow. It is a local treatment, meaning it targets the tumor and a margin of surrounding tissue. Radiation therapy can be delivered externally by a machine or internally via radioactive implants (brachytherapy). It is often used after surgery to eradicate any remaining cancer cells or as a primary treatment for inoperable tumors. Radiation is highly effective at controlling localized cancer, but it can also damage healthy cells in the treatment field. This can lead to side effects in nearby normal tissues (for example, radiation to the pelvis might affect the bowel or bladder). Modern techniques like IMRT and proton therapy aim to focus radiation more precisely to spare healthy tissue.

Chemotherapy [7]**:** Chemotherapy refers to drugs that kill rapidly dividing cells, targeting cancer cells systemically (throughout the body). Unlike surgery or localized radiation, chemotherapy is a systemic treatment that can reach cancer cells that have spread to lymph nodes or distant organs. Dozens of chemotherapy agents exist, often used in combinations. They work by various mechanisms to interfere with cell division or DNA replication. Chemotherapy has been shown to reduce recurrence and improve survival in many cancers. For example, adjuvant chemotherapy after surgical tumor removal can eliminate microscopic metastatic cells, and chemotherapy is the mainstay for blood cancers like leukemia. However, because these drugs target cell division, they also affect normal rapidly-dividing cells in the body – such as those in hair follicles, the gastrointestinal lining, or bone marrow. This explains common side effects like hair loss, nausea, and lowered blood cell counts. A major challenge is that cancers can develop drug resistance – genetic changes that allow tumor cells to survive despite chemotherapy – making some cancers hard to cure with current drugs.

Each of these conventional treatments has its limitations. Surgery cannot treat disease that has spread through the body; radiation is ineffective for widely metastatic cancer and can damage normal tissue; chemotherapy often causes systemic side effects and may fail to kill every cancer cell, allowing relapses. Therefore, oncologists often use a multimodal approach – for instance, surgery to remove a tumor, followed by radiation or chemotherapy (or both) to kill residual cells. Over the years, these standard therapies have markedly improved outcomes. Nonetheless, cure rates for metastatic cancers remain low, which spurred research into new treatments.

CHAPTER 03

Alternative and Emerging Approaches

In recent years, there has been tremendous progress in developing new cancer therapies beyond the traditional trio of surgery, radiation, and chemotherapy. These emerging approaches include targeted therapies that attack specific genetic or molecular features of cancer cells, and immunotherapy that enlists the patient's immune system to fight the tumor [4]. In addition, there is growing interest in complementary and alternative strategies, some deriving from natural products or repurposed non-cancer drugs, which are being studied in preclinical and clinical settings.

Targeted Therapies and Immunotherapy

Modern cancer research has identified many molecular drivers of cancer growth – for example, mutated proteins or abnormal signaling pathways that cancer cells depend on. This has led to targeted therapy drugs (like kinase inhibitors and monoclonal antibodies) that specifically block those cancer-driving molecules [8]. Unlike standard chemotherapy, targeted therapies aim to spare normal cells and often have different (sometimes more tolerable) side effect profiles. Examples include drugs like imatinib (for chronic myeloid leukemia, targeting the BCR-ABL fusion protein) and erlotinib (for some lung cancers with EGFR mutations). Targeted therapies have become standard care for many cancers with known mutations or aberrations, and they continue to be an active area of clinical trials [8].

Another revolutionary approach is immunotherapy, which has added a "fourth pillar" of cancer treatment in the last decade [9]. Immunotherapies activate the patient's own immune system to recognize and destroy cancer cells. One major class is immune checkpoint inhibitors (like anti-PD-1 or anti-CTLA-4 antibodies), which release the molecular "brakes" that tumors use to suppress immune cells [9]. These drugs have achieved unprecedented results in some advanced cancers. For instance, advanced melanoma (previously often fatal within a year) has seen 5-year survival rates exceed 50% with the introduction of checkpoint inhibitor immunotherapies [10]. Some patients experience complete, long-lasting remissions, essentially cured of metastatic disease, which was rarely seen with chemotherapy alone. While immunotherapy can cause immune-related side effects (as the activated immune cells can also attack normal organs), it has firmly established that enhancing the immune response can control or even eradicate tumors in a way not previously possible.

Medicinal Mushrooms in Cancer Therapy

Medicinal mushrooms have been used in traditional Asian medicine for centuries, and now they are being explored in modern oncology for their potential anti-cancer and immune-boosting properties. Notably, mushroom-derived compounds are already integrated into standard cancer

care in some countries. In Japan and China, extracts from the Turkey Tail mushroom (scientific name Coriolus versicolor, also known as Trametes versicolor) have been approved as adjunctive cancer treatments for over 30 years [11]. Two protein-bound polysaccharide preparations, PSK (Polysaccharide Krestin) and PSP, derived from C. versicolor, are used alongside chemotherapy or radiation. These mushroom extracts are immunomodulatory – they do not kill cancer cells directly like a chemotherapy drug, but they can stimulate the patient's immune system to better fight cancer and may improve tolerance to treatment. Research shows that β-glucans in these mushroom compounds activate immune cells such as natural killer cells and T-cells, and can increase the production of cytokines (immune signaling molecules) [11].

What does the scientific evidence say about mushrooms and cancer outcomes? A number of clinical studies, including randomized controlled trials, have evaluated medicinal mushroom supplements (such as Coriolus versicolor, Ganoderma lucidum [Reishi], Agaricus species, and others) in cancer patients. A 2020 review of clinical trials involving medicinal mushrooms in integrative oncology found that these supplements improved quality of life and helped reduce the side effects of conventional treatments in several studies [12].

For example, patients receiving mushrooms reported better appetite, energy, and immune blood counts during chemotherapy. Some trials also reported enhanced immune parameters – such as increased activity of natural killer cells – in patients taking mushroom extracts [12]. There is even evidence hinting at improved survival: in one randomized trial of advanced gastric cancer, patients who received the mushroom extract PSK alongside chemotherapy had a markedly higher 3-year survival rate (62%) compared to those who received chemotherapy alone (12.5%) [11]. A meta-analysis of observational studies examining the association between mushroom consumption and cancer risk found that higher mushroom consumption was associated with a 34% lower risk of cancer [13]. Importantly, these mushroom products have generally shown minimal toxicity in humans, with few reported adverse effects (occasional mild gastrointestinal upset) [12].

While a number of clinical studies, including randomized trials, have evaluated medicinal mushrooms like Coriolus versicolor and Reishi in cancer care, these studies are often limited in size and not designed as definitive treatment trials. Though some report improvements in quality of life, immune function, and even survival, the evidence remains preliminary. Larger, well-controlled studies are needed to confirm these promising early findings and clarify their role in oncology.

Exploring IV DMSO

Several clinical studies have explored the use of intravenous DMSO—often in combination with sodium bicarbonate and other supportive agents—as a potential treatment for cancer and cancer-related pain [1, 4]. A 2011 study in patients with metastatic prostate cancer found that IV DMSO combined with sodium bicarbonate led to marked symptom improvement, including pain relief, without notable side effects over a 90-day period [1]. A subsequent study in patients with advanced biliary adenocarcinoma administered continuous daily infusions of DMSO, sodium bicarbonate, magnesium sulfate, potassium chloride, and S-adenosylmethionine. After just two weeks, patients experienced over 50% reduction in abdominal pain, improved quality of life, and biochemical evidence of disease stabilization—again without significant adverse effects [2]. Another trial involving 26 patients with severe refractory cancer pain found that DMSO-bicarbonate infusions administered on a 10-day cycle provided safer and more effective pain control than conventional options, while also enhancing quality of life, reducing chemotherapy side effects, and potentially extending survival [3]. Mechanistic insights suggest DMSO's efficacy may stem from its ability to suppress NMDA and AMPA receptor-mediated ion fluxes, helping to calm membrane hyperexcitability—a key driver of chronic and intractable cancer pain [4].

CHAPTER 04

Repurposing Antiparasitic Drugs: Ivermectin and Fenbendazole



Figure 2. Summary of the antitumor mechanisms of ivermectin in different tumor types.



Figure 3. Summary of the antitumor mechanisms of ivermectin.

Based on the most comprehensive systematic review of ivermectin use in cancer patients to date, ivermectin appears to be safe—even in individuals undergoing active chemotherapy. Its broad range of anticancer mechanisms demonstrated in preclinical models, combined with anecdotal reports of cancer-related improvements, support its candidacy for repurposing as an oncologic therapy [20]."

While studies show that fenbendazole is generally safe in humans, it is only FDA-approved for use in animals. Mebendazole, a closely related compound with a similar mechanism of action, is FDA-approved for human use and has been studied in multiple cancer models.

Ivermectin: Ivermectin is a decades-old antiparasitic (notoriously used for river blindness and recently used for COVID-19). Interestingly, laboratory research has revealed that ivermectin also has a range of anti-cancer effects in cell cultures and animal models [14]. For example, studies have shown that ivermectin can trigger apoptosis (programmed cell death) in cancer cells, inhibit cancer cell proliferation, block tumor blood vessel growth (angiogenesis), and even help reverse chemotherapy resistance in certain tumor cells [14]. Mechanistically, ivermectin appears to act on multiple cellular pathways; one key target identified is the PAK1 kinase pathway, which is involved in cancer cell survival and proliferation. By modulating these pathways, ivermectin in preclinical models has been shown to slow

the growth of a variety of cancers (including breast, colon, ovarian, and brain cancer cells in lab studies). Moreover, some studies reported that combining ivermectin with standard chemotherapy drugs made the chemo more effective at killing cancer cells [14]. While no large scale clinical trial has yet shown that ivermectin can prolong survival or cure cancer, a significant number of case reports, as well as multiple small-scale pilot studies, have documented favorable results[1]. Nonetheless, ivermectin remains investigational for oncology use, and further rigorous research is required to confirm its safety and effectiveness in this context."

Mebendazole: Mebendazole (MBZ), an FDA-approved benzimidazole-class antiparasitic drug used for decades

to treat intestinal helminth infections, has recently garnered attention for its potential anticancer properties [15]. Structurally similar to fenbendazole, mebendazole inhibits microtubule polymerization by binding to β-tubulin, disrupting mitotic spindle formation and leading to cancer cell cycle arrest and apoptosis [16]. Preclinical studies have demonstrated that mebendazole exhibits broad-spectrum activity against glioblastoma, colorectal cancer, melanoma, and adrenocortical carcinoma [17]. In glioblastoma models, MBZ not only inhibited tumor growth but also prolonged survival in mice, potentially through inhibition of angiogenesis and VEGFR2 kinase pathways [18]. Importantly, mebendazole is well-tolerated, even at higher doses than those used for parasitic infections, and has demonstrated a favorable safety profile in both animal and human studies [19].

While both ivermectin and mebendazole have shown promising anti-cancer effects in preclinical studies—including cell cultures and animal models—these findings have not yet been confirmed in large-scale human clinical trials. Current evidence is limited to laboratory research, case reports, and small pilot studies. As such, no major clinical trial has demonstrated a clear survival benefit or therapeutic efficacy for either drug in cancer patients. At this time, ivermectin and mebendazole are not approved for the treatment of cancer, and their use in oncology remains investigational. Further rigorous clinical research is urgently needed to determine their safety and effectiveness in this context.

Methylene Blue

A systematic review by Taldaev et al. evaluated the effectiveness of methylene blue (MB) in preclinical models of photodynamic anticancer therapy—a treatment that combines a light-activated drug with targeted illumination to selectively destroy cancer cells. Methylene blue, a known photosensitizer, produces reactive oxygen species when exposed to specific wavelengths of light, triggering tumor cell death. Across ten animal studies, MB demonstrated significant antitumor activity, particularly against colorectal cancer, carcinoma, and melanoma, with tumor size reductions of up to 100%. Nanotechnology-enhanced formulations further improved efficacy, even at lower doses. While some variability was noted—especially in breast cancer and HeLa models—most studies showed MB slowed tumor progression relative to controls. These findings support further investigation into MB as a low-cost, light-activated anticancer agent with promising potential [21].

CHAPTER 05

Cancer Prevention: Known Strategies & Emerging Research

One of the important realiztions in oncology is that **cancer care is more than just attacking the tumor with surgery, radiation, or drugs** – it's also about engaging the patient's own biology, especially the immune system. The human immune system serves as a natural defense against cancer. In fact, researchers believe that most nascent cancers are identified and eliminated by the immune system before they ever manifest clinically, in a process known as immunosurveillance [20]. Immune cells such as cytotoxic T lymphocytes and natural killer (NK) cells constantly patrol the body for abnormal cells. When functioning properly, these cells can recognize cancer cells (which often display unusual proteins or stress signals) and destroy them [22]. Thus, optimizing the immune system through nutrition, supplementation, exercise, stress reduction, and other lifestyle factors can help prevent cancer proliferation [23, 24].

The Overlooked Metabolic Component of Cancer

Modern cancer theory has been dominated by the genetic mutation model, but an equally important and underappreciated factor is cancer's metabolic foundation. As early as the 1920s, Nobel laureate Otto Warburg demonstrated that cancer cells exhibit abnormal energy metabolism, favoring aerobic glycolysis—the fermentation of glucose even in the presence of oxygen—now known as the Warburg effect [26]. This shift supports rapid proliferation and creates an acidic tumor microenvironment that promotes invasion and immune evasion.



This metabolic vulnerability has opened the door to dietary strategies such as fasting and ketogenic diets, which aim to restrict glucose availability and elevate ketone bodies. Normal cells can adapt to ketones as a fuel source, but most cancer cells cannot, making this a selectively cytotoxic environment for tumors [27]. Studies have shown that intermittent fasting and carbohydrate restriction may slow tumor progression, enhance chemotherapeutic efficacy, and reduce treatment side effects [28, 29].

Immune Surveillance: Your Body's Daily Defense Against Cancer

A less discussed but foundational concept in oncology is that our bodies are constantly forming cancerous cells—but a healthy immune system neutralizes them before they pose a threat. This process, called immune surveillance, is supported by decades of evidence showing that T cells and natural killer (NK) cells routinely identify and destroy cells with DNA damage or abnormal surface markers [30].

However, this system can fail when the immune response is suppressed by chronic inflammation, malnutrition, aging, stress, or therapeutic immunosuppression. Additionally, tumor cells can evade detection by downregulating MHC class I molecules, secreting immunosuppressive cytokines like TGF-β, or recruiting regulatory T cells (Tregs) to suppress antitumor immunity [31, 32]. The rise of checkpoint inhibitors in cancer treatment further validates this model—these therapies don't attack tumors directly but remove the brakes from the immune system, enabling it to do what it was designed to do [33].

According to a 2024 review paper, up to 50% of all cancers may be preventable through sustained behavioral changes that reduce inflammation, hormonal imbalance, and immune suppression [25]. These modifiable factors include:

Maintain a Healthy Body Weight

Obesity increases systemic inflammation and insulin resistance, contributing to cancer development and progression. Excess weight is associated with a 60% increase in all-cause mortality, including cancer specific deaths.

Get Adequate Sleep & Mitigate Stress

Sleep deficiency and chronic stress are both associated with increased cancer risk, partly due to their negative impact on immune function and hormonal balance [44,45]. Poor sleep can impair immune surveillance, while excessive stress elevates cortisol and other stress hormones that may promote tumor growth. Just as inadequate rest or high stress can make one more susceptible to infections, they can also weaken the body's defenses against cancer. Aim for 7–9 hours of restorative sleep per night and practice regular stress-reduction techniques such as mindfulness, meditation, gentle exercise, or time in nature.

Adopt a Plant-Forward, Whole-Food Diet

Diets rich in vegetables, fruits, legumes, and whole grains reduce cancer risk, particularly for colorectal, breast, and prostate cancers. High fiber intake alone can lower colorectal cancer risk by up to 50%.

Limit Charred Red and Processed Meats

Frequent consumption of processed meats and charred red meats increases colorectal cancer risk by 20–30% due to carcinogenic compounds such as nitrosamines and HCAs.

Engage in Regular Physical Activity

Exercise reduces risk for multiple cancers by improving immune surveillance, reducing systemic inflammation, and regulating hormone levels. Risk reductions of 10–40% have been observed depending on cancer type. A recent landmark meta-analysis published in The Lancet Public Health found that walking 7,000 steps per day decreased the risk of cancer death by 37%. [42]

Avoid Tobacco Use

Tobacco remains the most potent lifestyle-related carcinogen, responsible for significantly increased risk across more than 15 cancer types.

Limit or Eliminate Alcohol

Alcohol is a Group 1 carcinogen linked to breast, colorectal, liver, and esophageal cancers. Even low levels of intake are associated with increased cancer risk.

Limit Sugar Intake

High glucose levels fuel cancer cell metabolism via the Warburg effect [40]. Reducing sugar and refined carbohydrate intake may help "starve" cancer cells of their preferred energy source and improve insulin sensitivity. This mechanism underlies the anticancer benefits observed with fasting and low-carbohydrate or ketogenic diets.

Ensure Adequate Vitamin D Levels

Low serum 25(OH)D has been associated with increased risk of breast, prostate, and colorectal cancer. Supplementation or moderate sun exposure may support immune function and reduce cancer susceptibility.

Key Ingredients Backed by Science

A growing body of research points to the powerful role of plant-based compounds in supporting the body's natural defenses against cancer. From ancient herbal remedies to modern nutraceuticals, certain botanicals have demonstrated promising anti-inflammatory, antioxidant, and anti-proliferative properties. Below are key ingredients—each backed by compelling scientific evidence—that may support cellular health and complement conventional therapies in cancer prevention and care.

Black Cumin Seed Oil (Thymoquinone)

Black cumin seed (Nigella sativa) contains the bioactive compound thymoquinone, which has been widely studied for its anti-cancer, antioxidant, and anti-inflammatory properties.

- **Mechanisms:** Thymoquinone induces apoptosis in cancer cells, inhibits angiogenesis, downregulates oncogenic signaling pathways (like NF-κB and PI3K/AKT), and enhances antioxidant defenses.
- **Preclinical Evidence:** In animal models, thymoquinone has shown inhibitory effects against breast, colon, pancreatic, and lung cancer cell lines.
- **Clinical Relevance:** Promising adjunctive effects in reducing tumor volume and improving chemotherapy tolerance, though larger trials are needed.[34]

Berberine

Berberine is a plant alkaloid used in traditional medicine that activates AMP-activated protein kinase (AMPK), a key regulator of cellular metabolism, inflammation, and tumor suppression.

- **Mechanisms:** AMPK activation suppresses cancer cell proliferation, induces apoptosis, inhibits tumor angiogenesis, improves insulin sensitivity, and assists in lowering serum glucose levels.[1]
- **Cancer Models:** Berberine has demonstrated efficacy in preclinical models of colorectal, prostate, liver, and breast cancer.
- **Synergy with Chemotherapy:** Berberine may enhance the sensitivity of cancer cells to chemotherapeutic agents and inhibit multidrug resistance pumps. [35]

Olive Leaf Extract (Oleuropein)

Olive leaf extract, particularly the compound oleuropein, exhibits antioxidant and anti-proliferative properties.

- **Mechanisms:** Oleuropein scavenges free radicals, inhibits cancer cell cycle progression, and enhances apoptosis.[43]
- **In Vitro Studies:** It has shown selective cytotoxicity against breast, prostate, and colorectal cancer cell lines.
- **Adjunct Potential:** Oleuropein enhances immune surveillance and may sensitize tumors to conventional therapies. [35]

Oregano Oil (Carvacrol)

Oregano oil contains carvacrol, a phenolic monoterpenoid with notable anti-cancer and antimicrobial activity.

- **Mechanisms:** Carvacrol induces cell cycle arrest, mitochondrial-mediated apoptosis, and inhibits tumor angiogenesis.
- **Research Highlights:** In vitro studies show strong anti-proliferative effects in breast, cervical, liver, and colon cancer cell lines.
- **Immune Support:** It also exhibits anti-inflammatory actions that may help modulate the tumor microenvironment. [36]

Garlic (Allium sativum)

Garlic contains organosulfur compounds like allicin and DADS with potent anticancer, antioxidant, and immune-enhancing effects.

- **Mechanisms:** Induces apoptosis, inhibits angiogenesis, modulates immune function, and enhances detoxification pathways.
- **Clinical Use:** Epidemiological studies link high garlic intake to reduced risks of colorectal, stomach, and prostate cancer; supplements have shown immune-stimulating effects in humans. [37]

Turmeric (Curcumin)

Curcumin, the active polyphenol in turmeric, exhibits broad anti-cancer activity through multiple mechanisms.

- **Mechanisms:** Downregulates NF-κB, STAT3, and other inflammation-linked cancer pathways; promotes apoptosis; suppresses metastasis and angiogenesis.
- **Clinical Use:** Several phase I/II trials support its role in reducing tumor markers and inflammation in colorectal and pancreatic cancer patients. [38]

Green Tea (EGCG)

Green tea contains epigallocatechin gallate (EGCG), a catechin with strong antioxidant and cancer-preventive properties.

- **Mechanisms:** EGCG interferes with multiple signaling pathways (e.g., MAPK, PI3K/AKT), inhibits proliferation, and induces apoptosis.
- **Population Studies:** Green tea consumption is linked with reduced incidence of breast, prostate, and colorectal cancers. [39]

CHAPTER 06

Conclusion: Clarity Through Science & Hope

At The Wellness Company, we believe that health freedom begins with access to clear, evidence-based information. In a world where confusion often overshadows facts, our mission is to provide accurate, science-backed knowledge—so you can better understand what's happening within your body and make empowered decisions about your health.

Cancer is a multifaceted disease that requires more than conventional treatment alone. While surgery, chemotherapy, and radiation remain foundational, emerging therapies—such as immunotherapy, targeted drugs, medicinal mushrooms, and repurposed agents like ivermectin and mebendazole—are reshaping care. At the same time, robust evidence shows that up to 50% of cancers may be preventable through lifestyle changes that reduce inflammation, support immune function, and correct metabolic imbalance. Diet, exercise, vitamin D status, and avoidance of tobacco and alcohol are central to long-term prevention.

As research continues to evolve, the future of cancer care lies in integrating medical innovation with proactive strategies that strengthen the body's natural defenses. We're honored to walk with you on this journey—bringing you trusted insights that inform, empower, and support whole-body wellness.

The Wellness Company

WWW.TWC.HEALTH

Citations:

1. Brown JS, et al. Updating the Definition of Cancer. Mol Cancer Res. 2023 Nov 1;21(11):1142-1147. doi: 10.1158/1541-7786.MCR-23-0411. PMID: 37409952.
2. Sonnenschein C, et al. The aging of the 2000 and 2011 Hallmarks of Cancer reviews: a critique. J Biosci. 2013 Sep;38(3):651-663. doi: 10.1007/s12038-013-9335-6. PMID: 23938395.
3. Cooper GM. The Cell: A Molecular Approach. 2nd edition. Sunderland (MA): Sinauer Associates; 2000. The Development and Causes of Cancer. Available from: https://www.ncbi.nlm.nih.gov/books/NBK9963/.
4. Debela DT, et al. New approaches and procedures for cancer treatment: Current perspectives. SAGE Open Med. 2021 Aug 12;9:20503121211034366. doi: 10.1177/20503121211034366. PMID: 34408877.
5. Wyld L, et al. The evolution of cancer surgery and future perspectives. Nat Rev Clin Oncol. 2015 Feb;12(2):115-124. doi: 10.1038/nrclinonc.2014.191. Epub 2014 Nov 11. PMID: 25384943.
6. Baskar R, et al. Cancer and radiation therapy: current advances and future directions. Int J Med Sci. 2012;9(3):193-199. doi: 10.7150/ijms.3635. Epub 2012 Feb 27. PMID: 22408567.
7. Hossain MB, et al. Chemotherapy. Cancer Treat Res. 2023;185:49-58. doi: 10.1007/978-3-031-27156-4_3. PMID: 37306903.
8. Li J, et al. Kinase Inhibitors and Kinase-Targeted Cancer Therapies: Recent Advances and Future Perspectives. Int J Mol Sci. 2024 May 17;25(10):5489. doi: 10.3390/ijms25105489. PMID: 38791529; PMCID: PMC11122109.
9. Ling SP, et al. Role of Immunotherapy in the Treatment of Cancer: A Systematic Review. Cancers (Basel). 2022 Oct 24;14(21):5205. doi: 10.3390/cancers14215205. PMID: 36358624.
10. Nebhan CA, et al. Predictive biomarkers of response to immune checkpoint inhibitors in melanoma. Expert Rev Anticancer Ther. 2020 Feb;20(2):137-145. doi: 10.1080/14737140.2020.1724539. Epub 2020 Feb 5. PMID: 31997676.
11. Venturella G, et al. Medicinal Mushrooms: Bioactive Compounds, Use, and Clinical Trials. Int J Mol Sci. 2021 Jan 10;22(2):634. doi: 10.3390/ijms22020634. PMID: 33435246.
12. Jeitler M, et al. Significance of Medicinal Mushrooms in Integrative Oncology: A Narrative Review. Front Pharmacol. 2020 Nov 11;11:580656. doi: 10.3389/fphar.2020.580656. PMID: 33424591.
13. Ba DM, et al. Higher Mushroom Consumption Is Associated with Lower Risk of Cancer: A Systematic Review and Meta-Analysis of Observational Studies. Adv Nutr. 2021 Oct 1;12(5):1691-1704. doi: 10.1093/advances/nmab015. PMID: 33724299.
14. Tang M, et al. Ivermectin, a potential anticancer drug derived from an antiparasitic drug. Pharmacol Res. 2021 Jan;163:105207. doi: 10.1016/j.phrs.2020.105207. Epub 2020 Sep 21. PMID: 32971268.
15. Doudican N, et al. Mebendazole induces apoptosis via Bcl-2 inactivation in chemoresistant melanoma cells. Mol Cancer Res. 2008 Aug;6(8):1308-1315. doi: 10.1158/1541-7786.MCR-07-2159. Epub 2008 Jul 30. PMID: 18667591.
16. Martarelli D, et al. Mebendazole inhibits growth of human adrenocortical carcinoma cell lines implanted in nude mice. Cancer Chemother Pharmacol. 2008 Apr;61(5):809-817. doi: 10.1007/s00280-007-0538-0. Epub 2007 Jun 21. PMID: 17581752.

17. Guerini AE, et al. Mebendazole as a Candidate for Drug Repurposing in Oncology: An Extensive Review of Current Literature. Cancers (Basel). 2019 Aug 31;11(9):1284. doi: 10.3390/cancers11091284. PMID: 31480477.
18. Bai RY, et al. Brain Penetration and Efficacy of Different Mebendazole Polymorphs in a Mouse Brain Tumor Model. Clin Cancer Res. 2015 Aug 1;21(15):3462-3470. doi: 10.1158/1078-0432.CCR-14-2681. Epub 2015 Apr 10. PMID: 25862759.
19. Silber SA, et al. Efficacy and Safety of a Single-Dose Mebendazole 500 mg Chewable, Rapidly-Disintegrating Tablet for Ascaris lumbricoides and Trichuris trichiura Infection Treatment in Pediatric Patients: A Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study. Am J Trop Med Hyg. 2017 Dec;97(6):1851-1856. doi: 10.4269/ajtmh.17-0108. Epub 2017 Aug 31. PMID: 29016336.
20. Gonzalez H, et al. Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev. 2018 Oct 1;32(19-20):1267-1284. doi: 10.1101/gad.314617.118. PMID: 30275043.
21. Janakiram NB, et al. Prevention and treatment of cancers by immune modulating nutrients. Mol Nutr Food Res. 2016 Jun;60(6):1275-1294. doi: 10.1002/mnfr.201500884. Epub 2016 Mar 9. PMID: 26833775.
22. Lyu DW. Immunomodulatory effects of exercise in cancer prevention and adjuvant therapy: a narrative review. Front Physiol. 2024 Jan 4;14:1292580. doi: 10.3389/fphys.2023.1292580. PMID: 38239881.
23. Marino P, et al. Healthy Lifestyle and Cancer Risk: Modifiable Risk Factors to Prevent Cancer. Nutrients. 2024 Mar 11;16(6):800. doi: 10.3390/nu16060800. PMID: 38542717.
24. Lai Y, Guan X, Chen X, Chen J, Zhang X, Lu M. A review of ivermectin use in cancer patients: Is it time to repurpose ivermectin in cancer treatment? Acta Pol Pharm - Drug Res. 2024;81(6):913-929. doi:10.32383/appdr/200570.
25. WARBURG O. On the origin of cancer cells. Science. 1956;123(3191):309-314. doi:10.1126/science.123.3191.309
26. Seyfried TN, Flores RE, Poff AM, D'Agostino DP. Cancer as a metabolic disease: implications for novel therapeutics. Carcinogenesis. 2014;35(3):515-527. doi:10.1093/carcin/bgt480
27. de Groot S, Pijl H, van der Hoeven JJM, Kroep JR. Effects of short-term fasting on cancer treatment. J Exp Clin Cancer Res. 2019;38(1):209. Published 2019 May 22. doi:10.1186/s13046-019-1189-9
28. Klement RJ, Champ CE. Calories, carbohydrates, and cancer therapy with radiation: exploiting the five R's through dietary manipulation. Cancer Metastasis Rev. 2014;33(1):217-229. doi:10.1007/s10555-014-9495-3
29. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004;21(2):137-148. doi:10.1016/j.immuni.2004.07.017
30. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011;331(6024):1565-1570. doi:10.1126/science.1203486
31. Spranger S, Gajewski TF. Mechanisms of Tumor Cell–Intrinsic Immune Evasion. Annu Rev Cancer Biol. 2018;2:213–228. doi:10.1146/annurev-cancerbio-030617-050606

32. Alturki NA. Review of the Immune Checkpoint Inhibitors in the Context of Cancer Treatment. J Clin Med. 2023;12(13):4301. Published 2023 Jun 27. doi:10.3390/jcm12134301
33. Woo CC, Kumar AP, Sethi G, Tan KH. Thymoquinone: potential cure for inflammatory disorders and cancer. Biochem Pharmacol. 2012;83(4):443-451. doi:10.1016/j.bcp.2011.09.029
34. Rauf A, Abu-Izneid T, Khalil AA, et al. Berberine as a Potential Anticancer Agent: A Comprehensive Review. Molecules. 2021;26(23):7368. Published 2021 Dec 4. doi:10.3390/molecules26237368
35. Rishmawi S, Haddad F, Dokmak G, Karaman R. A Comprehensive Review on the Anti-Cancer Effects of Oleuropein. Life (Basel). 2022;12(8):1140. Published 2022 Jul 28. doi:10.3390/life12081140
36. Arunasree KM. Anti-proliferative effects of carvacrol on a human metastatic breast cancer cell line, MDA-MB 231. Phytomedicine. 2010;17(8-9):581-588. doi:10.1016/j.phymed.2009.12.008
37. Fleischauer AT, Arab L. Garlic and cancer: a critical review of the epidemiologic literature. J Nutr. 2001;131(3s):1032S-40S. doi:10.1093/jn/131.3.1032S
38. Wilken R, Veena MS, Wang MB, Srivatsan ES. Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma. Mol Cancer. 2011;10:12. Published 2011 Feb 7. doi:10.1186/1476-4598-10-12
39. Singh BN, Shankar S, Srivastava RK. Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications. Biochem Pharmacol. 2011;82(12):1807-1821. doi:10.1016/j.bcp.2011.07.093
40. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029-1033. doi:10.1126/science.1160809
41. Lai Y, Guan X, Chen X, Chen J, Zhang X, Lu M. A review of ivermectin use in cancer patients: Is it time to repurpose ivermectin in cancer treatment? Acta Pol Pharm. 2024;81(6):913-929. doi:10.32383/appdr/200570.
42. Saint-Maurice PF, Coughlan D, Chudasama YV, et al. Association of daily step counts with mortality among US adults. Lancet Public Health. 2025;10(1):e42-e52. doi:10.1016/S2468-2667(25)00164-1.
43. Almatroodi SA, Alsahli MA, Rahmani AH. Berberine: An Important Emphasis on Its Anticancer Effects through Modulation of Various Cell Signaling Pathways. Molecules. 2022;27(18):5889. Published 2022 Sep 10. doi:10.3390/molecules27185889
44. 1. Garbarino S, Lanteri P, Bragazzi NL, Magnavita N, Scoditti E. Role of sleep deprivation in immune-related disease risk and outcomes. Commun Biol. 2021;4(1):1304. Published 2021 Nov 18. doi:10.1038/s42003-021-02825-4
45. 2. Dai S, Mo Y, Wang Y, et al. Chronic Stress Promotes Cancer Development. Front Oncol. 2020;10:1492. Published 2020 Aug 19. doi:10.3389/fonc.2020.01492

www.twc.health